Plain-English translation of NCT07785193 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called , given as a subcutaneous injection (a shot under the skin), for people with advanced solid tumors. The study will look at whether the medication is safe, how well it works, and how your body processes it. About 29 people will participate across multiple hospitals.
Many people with advanced solid tumors stop responding to current treatments like checkpoint inhibitors. This medication is being tested to see if it offers a new option for patients whose cancer has progressed despite standard therapy.
You will receive an injection of the medication under your skin once every three weeks. Each treatment cycle lasts 21 days, and you will continue treatment until your cancer progresses, you experience unacceptable side effects, or you choose to stop. Throughout the study, you'll have regular visits to monitor your health, have blood tests, and have scans to see how your tumors are responding.
AI-generated summary from trial data · Aug 27, 2026 · Not medical advice
Australia